[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.1007/s10059-009-0116-x

Enhanced Cytotoxicity of 5-FU by bFGF through Up-Regulation of Uridine Phosphorylase 1

Im, Young-Sam (Department of Biochemistry, College of Medicine, Chungbuk National University)
Shin, Hea Kyeong (Department of Plastic Surgery, College of Medicine, Dongguk University)
Kim, Hye-Ryun (Department of Biochemistry, College of Medicine, Chungbuk National University)
Jeong, So-Hee (Department of Biochemistry, College of Medicine, Chungbuk National University)
Kim, Seung-Ryul (Department of Biochemistry, College of Medicine, Chungbuk National University)
Kim, Yong-Min (Department of Orthopaedic Surgery, College of Medicine, Chungbuk National University)
Lee, Do Hyung (Gyeonggi Regional Research Center, Hankyoung National University)
Jeon, Seong-Ho (College of Pharmacy, Kangwon National University)
Lee, Hyeon-Woo (Department of Pharmacology, School of Dentistry, Kyung Hee University)
Choi, Joong-Kook (Department of Biochemistry, College of Medicine, Chungbuk National University)

Abstract

Anti cancer agent 5-FU (Fluoro Uracil) is a prodrug that can be metabolized and then activated to interfere with RNA and DNA homeostasis. However, the majority of administered 5-FU is known to be catabolized in vivo in the liver where Dihydropyrimidine dehydrogenase (DPD) is abundantly expressed to degrade 5-FU. The biological factors that correlate with the response to 5-FU-based chemotherapy have been proposed to include uridine phosphorylase (UPP), thymidine phosphorylase (TPP), p53 and microsatellite instability. Among these, the expression of UPP is known to be controlled by cytokines such as $TNF-{\alpha}$ , IL1 and $IFN-{\gamma}$ . Our preliminary study using a DNA microarray technique showed that basic fibroblast growth factor (bFGF) markedly induced the expression of UPP1 at the transcription level. In the present study, we investigated whether bFGF could modulate the expression of UPP1 in osteo-lineage cells and examined the sensitivity of these cells to 5-FU mediated apoptosis.

Keywords

5-DFUR (= 5-dFURd); 5-FU; apoptosis; ATDC5 chondroprogenitor cells; bFGF; C2C12 pre-myoblasts; $NF{\kappa}B$ ; uridine phosphorylase;

Citations & Related Records

Times Cited By KSCI : 2 (Citation Analysis)
Times Cited By Web Of Science : 5 (Related Records In Web of Science)

Reference
Cited By KSCI

1	Diasio, R.B., and Harris, B.E. (1989). Clinical pharmacology of 5- fluorouracil. Clin. Pharmacokinet. 16, 215-237 DOI ScienceOn
2	Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355,1041-1047 DOI ScienceOn
3	el Kouni, M.H., Naguib, F.N., Park, K.S., Cha, S., Darnowski, J.W., and Soong, S.J. (1990). Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol. 40, 2479-2485 DOI ScienceOn
4	Voboril, R., Hochwald, S.N., Li, J., Brank, A., Weberova, J., Wessels, F., Moldawer, L.L., Camp, E.R., and MacKay, S.L. (2004). Inhibition of NF-kappa B augments sensitivity to 5- fluorouracil/folinic acid in colon cancer. J. Surg. Res. 120, 178-188 DOI ScienceOn
5	Seymour, M.T., Slevin, M.L., Kerr, D.J., Cunningham, D., James, R.D., Ledermann, J.A., Perren, T.J., McAdam, W.A., Harper, P.G., Neoptolemos, J.P., et al. (1996). Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J. Clin. Oncol. 14, 2280-2288 DOI
6	Al Safarjalani, O.N., Zhou, X.J., Rais, R.H., Shi, J., Schinazi, R.F., Naguib, F.N., and El Kouni, M.H. (2005). 5-(Phenylthio) acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother. Pharmacol. 55, 541-551 DOI ScienceOn
7	Kim, S., Park, D.H., and Shim, J. (2008). Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans. Mol. Cells 26, 344-349 PUBMED
8	Giacchetti, S., Perpoint, B., Zidani, R., Le, B.N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J.F., Letourneau, Y., Coudert, B., et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18,136-147
9	Baynes, J.W., and Dominiczak, M.H. (2005). Medical biochem-mistry (Elsevier Mosby), pp.417-423
10	Geng, Y., Gheuens, E., and de Bruijn, E.A. (1991). Activation and cytotoxicity of 5'-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. Biochem. Pharmacol. 41, 301-303 DOI ScienceOn
11	Johnston, P.G., and Kaye, S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12, 639-646 DOI ScienceOn
12	Wan, L., Cao, D., Zeng, J., Yan, R., and Pizzorno, G. (2006). Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5′-deoxy-5-fluorouridine in breast cancer cells. Mol. Pharmacol. 69, 1389-1395 DOI ScienceOn
13	Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338 DOI ScienceOn
14	Cao, D., and Pizzorno, G. (2004). Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc.) 40, 431-443 DOI PUBMED ScienceOn
15	Lee, S.J., Lee, H.K., Cho, S.Y., Choi, J.K., Shin, H.K., Kwak, E.J., Cho, M.R., Kim, H.R., Kim, S.R., Kim, Y.M., et al. (2008). Identification of osteogenic purmorphamine deriva-tives. Mol. Cells 26, 380-386 PUBMED
16	Moyer, J.D., Oliver, J.T., and Handschumacher, R.E. (1981). Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41, 3010-3017 PUBMED
17	Greco, F.A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marshall, E.M., Buys, S.S., Froimtchuk, M.J., Schuller, J., Schuchter, L., et al. (1996). Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J. Clin. Oncol. 14, 2674-2681 DOI
18	Schwartz, E.L., Wan, E., Wang, F.S., and Baptiste, N. (1998). Regulation of expression of thymidine phosphorylase/plateletderived endothelial cell growth factor in human colon carcinoma cells. Cancer Res. 58, 1551-1557 PUBMED

6	(2009) ACS chemical biology Novel Chemically Defined Approach To Produce Multipotent Cells from Terminally Differentiated Tissue Syncytia / 6 (6) , 553
14	(2009) Proceedings of the National Academy of Sciences of the United States of America Coordination of the transcriptome and metabolome by the circadian clock / 109 (14) , 5541
5	(2009) BMB reports FGF-2 inhibits TNF-α mediated apoptosis through up-regulation of Bcl2-A1 and Bcl-xL in ATDC5 cells / 45 (5) , 287
5	(2009) Oncology reports Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells / 29 (5) , 1689
7	(2009) Cancers Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism / 10 (7) , 240
4	(2009) Gastroenterology Vitamin D Regulation of the Uridine Phosphorylase 1 Gene and Uridine-Induced DNA Damage in Colon in African Americans and European Americans / 155 (4) , 1192
21	(2009) Cancer research : the official organ of the American Association for Cancer Research, Inc 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <I>PIK3CA</I>-Mutant Colorectal Cancers / 80 (21) , 4815
22	(2021) Cancers FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance / 13 (22) , 5796